Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

DNA’s chemical cousin, RNA, was the messenger that carries DNA instructions from the double helix in the cell’s nucleus to ...

In 1957, just four years after Francis Crick and other scientists solved the riddle of DNA’s structure—the now famous double ...

A clinical-stage biotech company headquartered in San Diego, focused on advancing RNA-based medicines for serious and ...

Here, we define a requirement for neural activity in mobilizing the antioxidant defenses of the nematode Caenorhabditis elegans both during chronic oxidative stress and prior to its onset. We show ...

Canceling federal mRNA vaccine projects threatens much more than pandemic response, according to Michigan State University’s Director of the Precision Health Program Anna Moore. Last week, Secretary ...

Indian American researcher to study how cells “silence” transposons, genetic elements that can disrupt the function of genes ...

Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and announces that the U.S. Food and Drug Administration ...

University of North Carolina Lineberger Comprehensive Cancer Center researchers have developed a "two-in-one" molecule that can simultaneously turn off two notoriously difficult-to-target cancer ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from ...